Avricore Health (AVCRF) Research & Development (2009 - 2025)

Avricore Health has disclosed Research & Development across 16 years of filings, most recently posting $8693.5 for Q3 2025.

• In Q3 2025, Research & Development rose 1247.64% year-over-year to $8693.5; the TTM figure through Sep 2025 stood at $99909.1 (up 40.37% YoY), while the FY2024 annual figure was $69634.8, up 166.03% from the prior year.
• Research & Development declined to $8693.5 in Q3 2025, from $16206.1 in the prior quarter.
• Over the last five years, Research & Development for AVCRF reached as high as $44599.5 in Q1 2024 and fell as low as $92.15 in Q3 2021.
• The 5-year median for Research & Development is $11106.3 (2022), against an average of $15547.6.
• Annual changes were most pronounced in 2022 — Research & Development surged 11952.24% — and 2023, when it sank 79.26%.
• A 5-year view of Research & Development shows it stood at $10257.0 in 2021, then tumbled by 50.84% to $5042.7 in 2022, then slipped by 9.19% to $4579.1 in 2023, then soared by 839.5% to $43021.1 in 2024, then plunged by 79.79% to $8693.5 in 2025.
• According to Business Quant data, Research & Development over the past three periods registered $8693.5, $16206.1, and $31988.5 for Q3 2025, Q2 2025, and Q1 2025 respectively.